AFP and digestive system neoplasm: The problem with AFP as a reliable HCC biomarker is that HCC is positive for the protein in only 60%-80% of cases, and false positives make it difficult to distinguish early stage HCC from other disorders, such as acute hepatitis and cirrhosis, as well as embryonic tumors and certain gastrointestinal tumors.